Toggle light / dark theme

The APOE-R136S mutation protects against APOE4-driven Tau pathology, neurodegeneration and neuroinflammation

Nelson et al. present a detailed biomolecular study of how the APOE-R136S mutation protects against Alzheimer’s disease (AD) in mice and in patient-derived cells. Lots of data on glial contributions and transcriptomic changes. I see this as an excellent target for gene therapies aiming to combat AD. So do the folks at Lexeo Therapeutics (an exciting company you should check out!)


Nelson et al. report that the APOE-R136S mutation protects against APOE4-promoted Alzheimer’s disease pathologies, including phosphorylated Tau accumulation, neuroinflammation and neurodegeneration, in mouse and human neuron models.

FOXO3: The Longevity Switch Inside Our Cells — Decoding the Master Regulator of Aging, Stress, and Disease

Aging is a universal biological process, yet the reasons why some individuals live significantly longer and healthier lives have long puzzled scientists. Among the genes linked to exceptional longevity, FOXO3 consistently stands out as one of the most influential “master controllers” of cellular resilience. This single transcription factor integrates signals from stress, metabolism, DNA repair, and stem cell biology, orchestrating a vast genetic program that determines how cells survive, adapt, or age [1].

In recent years, interest in FOXO3 has surged across aging research, regenerative medicine, oncology, and precision therapeutics. Variants of the FOXO3 gene are strongly associated with centenarian populations worldwide, while disruptions in its regulatory network contribute to multiple disorders, including cancer, neurodegeneration, metabolic decline, and tissue degeneration. With advances in computational biology and pathway analysis, it is now possible to map FOXO3’s complex signaling network and uncover new therapeutic strategies.

This blog post explores FOXO3’s multifaceted biological roles, its influence on disease, and what our curated data from TRANSFAC®, TRANSPATH®, and HumanPSD™ reveals about the FOXO3 regulatory network. The goal is to provide a scientifically rich yet accessible overview that sparks curiosity among researchers studying aging, longevity, and systems-level biology.

Hidden mitochondrial genes emerge as mealybugs encode two genes on one DNA stretch

What if a single sentence could carry two completely different meanings, one when read forward and another when read backward? In a new study, researchers at Arizona State University have discovered a biological version of this idea. Working with the mitochondria of a tiny insect called the citrus mealybug, the team found that the same stretch of DNA can carry two different genes—sets of genetic instructions used by the cell—with one encoded on each strand of the DNA’s ladder-like structure.

The finding expands scientists’ understanding of how DNA can store genetic information and helps solve a mystery that has puzzled researchers for years. The findings are published in the journal Proceedings of the National Academy of Sciences.

“This kind of paper is what makes running a lab so fun. Born from a spark of individual brilliance—not mine—but accomplished as a collective effort,” says John McCutcheon. “The idea that these two critically important genes could be mirrored on the same piece of DNA has been around a long time, and so it’s a thrill to be part of the team that proved this speculative idea was, in fact, reality.”

Studying the Neural Circuit Mechanisms of Cognition Using Rodents

Brody is professor of neuroscience and molecular biology at Princeton University and a Howard Hughes Medical Institute Investigator. His research focuses is on novel quantitative behaviors that allow exploring high-level cognitive questions using powerful emerging tools for studying neural mechanisms in rodents. Brody’s group uses rats to investigate the neural bases of decision making, working memory, and executive control, using a combination of high-throughput semiautomated behavior as well as computational, electrophysiological, pharmacological and optogenetic methods.

Understanding and targeting erythroid cell metabolism

Red blood cell (RBC) production, or erythropoiesis, serves as a paradigm for studying cellular differentiation in both physiological and pathological contexts. While the transcriptional and epigenetic programs controlling erythropoiesis are well characterized, the metabolic regulation of this complex process remains underexplored. Recent discoveries that pyruvate kinase activators improve outcomes in sickle cell disease and thalassemia underscore the therapeutic potential of targeting metabolism in RBC disorders. However, further progress is limited by an incomplete understanding of the metabolic networks supporting erythropoiesis and RBC function.

Nanomedicine discovery uses salt to overcome major obstacle in gene therapy

Researchers at the University of Houston’s College of Pharmacy have discovered an unexpectedly simple strategy to improve the performance of mRNA vaccines and gene therapeutics: adding salt. The findings, published in Small, address one of the biggest challenges facing modern gene medicine—getting fragile therapeutic material to the right place inside cells.

“We are introducing salt-loaded lipid nanoparticles as a novel and broadly applicable design principle for gene delivery,” said Fanfei Meng, assistant professor and Presidential Frontier Faculty member in the Department of Pharmacological and Pharmaceutical Sciences. “What makes this exciting is that we can significantly improve delivery efficiency without needing to invent entirely new materials.”

Lipid nanoparticles, or LNPs, are tiny fat-based delivery vehicles widely used to transport fragile genetic material into cells. They became widely recognized during the COVID-19 pandemic through mRNA vaccines developed by Moderna and Pfizer. Today, scientists are also using LNPs to develop new treatments for cancer, rare diseases and genetic disorders.

Many cancers originate from a single cancer cell and evolve through early bursts of chromosome changes

A comprehensive multi-cancer study by researchers at The University of Texas MD Anderson Cancer Center has revealed that cancer cells within tumors are genetically diverse, yet all carry the same core genetic changes that can be traced back to a common ancestral cell, providing a single-cell view of how tumors adapt, survive and diversify. Understanding this helps explain why some cancer cells manage to survive treatment, paving the way for more tailored diagnostic and therapeutic strategies.

The study, published in Cancer Discovery, was led by Nicholas Navin, Ph.D., chair of Systems Biology. The research shows that cancer cells do not evolve slowly over time, but rather grow through sudden bursts of rapid genetic changes that include copy number alterations (CNAs)—gains or losses of entire sections of DNA. This creates a family tree of distinct new subpopulations that can influence tumor aggressiveness, metastasis and treatment response.

“Our findings provide the clearest views to date of how cancers originate and evolve at the single-cell level,” Navin said. “By revealing both the shared early genetic events and the bursts that drive ongoing diversity, we now have a roadmap for developing smarter clinical diagnostic and treatment strategies to improve patient outcomes.”

Scientists Just Found A Quantum Computer Hiding Inside You

FREE GUIDE: 📘 The Content Creator’s AI Blueprint – https://FirstMovers.ai/blueprint/

For 100 years the rule was absolute: to see quantum behavior, you freeze your machine to near absolute zero. In August 2025, a team at the University of Chicago broke it inside a living cell.

They turned enhanced yellow fluorescent protein from the same family that makes jellyfish glow into a working qubit, and detected the signal inside living mammalian cells and bacteria. Published in *Nature*, named a top-ten breakthrough of the year.

What you’ll learn:
✅ How a glowing protein became a real qubit.
✅ Why nature solved this before our best labs did.
✅ What genetically encoded quantum sensors mean by 2030.

There’s quantum machinery glowing inside you right now — and it’s more elegant than anything we’ve engineered.

#QuantumPhysics #Consciousness #Science.

Reliable Detection of SGLT2 Protein by Knockout-Based Antibody Characterization

BACKGROUND: SGLT2 (sodium-glucose cotransporter 2) mediates renal glucose reabsorption, and its pharmacological inhibition exerts cardio-and renoprotective benefits. Despite widespread clinical interest, reliable detection of SGLT2 protein remains challenging due to concerns regarding antibody specificity. METHODS: Eight commercially available anti-SGLT2 antibodies were evaluated by immunohistochemistry and Western blotting using kidneys and hearts from genetically engineered Sglt2-deficient mice and rats. Human kidney tissues, including renal cell carcinoma samples, were also examined. RESULTS: Among the antibodies tested, ab306558 and HPA041603 showed specific immunostaining in rodent kidneys, with minimal background in wild-type tissues and complete absence of staining in Sglt2-deficient samples. However, ab306558 was unsuitable for human samples because of nonspecific staining.

/* */